EP
INDV icon

Evelyn Partners’s Indivior Pharmaceuticals INDV Stock Holding History

Evelyn Partners’s Portfolio INDV Stock Details INDV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$635K Buy
+15,474
New +$561K ﹤0.01% 199

Other funds holding INDV

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
OCM
Oaktree Capital Management Los Angeles, California $7.21B AUM 45.97% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $36.7B AUM 74.15% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Evelyn Partners's INDV Position: Q2 2026 in Review

Evelyn Partners opened a new position in Indivior Pharmaceuticals (INDV) in Q2 2026: 15,474 shares worth $635K. The stake represents ﹤0.01% of the portfolio and ranks #199 among its holdings.

315 funds tracked by Wall St. Rank hold INDV as of Q2 2026.

  • Evelyn Partners held 15,474 shares of Indivior Pharmaceuticals worth $635K as of Q2 2026.
  • Indivior Pharmaceuticals was a new Evelyn Partners position in Q2 2026.
  • Indivior Pharmaceuticals made up ﹤0.01% of Evelyn Partners's portfolio in Q2 2026, its #199 holding.
  • 315 funds tracked by Wall St. Rank held Indivior Pharmaceuticals as of Q2 2026.

Based on Evelyn Partners's 13F filing for Q2 2026, filed 7 Aug 2026.